Agilon health, inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed June 5, 2024, regarding an event occurring June 4, 2024. It reports the appointment of Jeff Schwaneke as Chief Financial Officer and Executive Vice President, effective July 1, 2024. The filing is not a periodic financial report and does not cover a financial reporting period.
Key Financial and Other Metrics
- Annual base salary: $625,000.
- Annual target bonus: 75% of base salary, or $468,750 if fully earned at target.
- Initial sign-on equity awards: $3.5 million in aggregate grant-date fair value, consisting of $2.5 million of time/service-vested RSUs and $1.0 million of PSUs subject to a 100% share-price appreciation hurdle.
- Additional fiscal 2024 equity awards: $3.5 million in aggregate grant-date fair value, consisting of 50% PSUs, 25% RSUs and 25% stock options, with terms generally consistent with awards to other executive officers.
- Potential fiscal 2025 annual equity award: $3.5 million in aggregate grant-date fair value if Mr. Schwaneke remains employed when those awards are granted, with terms generally consistent with awards to other executive officers.
- Sign-on bonus: $300,000, payable in a single lump sum 30 to 45 days after the effective date.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity or operating performance metrics.
Material Changes Versus the Prior Comparable Period
- Jeff Schwaneke was appointed CFO and Executive Vice President effective July 1, 2024.
- In connection with the appointment, he will resign from the Company’s Board of Directors.
- The filing does not identify the departing CFO or provide comparative financial results.
Outlook, Risks, Contingencies and Unusual Items
- Mr. Schwaneke has more than 27 years of finance and operational experience, including 15 years in managed care. He most recently served as Executive Vice President, Health Care Enterprises at Centene Corporation and previously served as Centene’s CFO and Treasurer.
- The PSU sign-on award includes a 100% share-price appreciation hurdle and may have its performance period shortened upon a change in control.
- The employment agreement and offer letter will be filed as exhibits to the Company’s Form 10-Q for the quarter ending June 30, 2024; the full terms are not included in this filing.
- The Company stated that there are no arrangements relating to the appointment involving another person, no family relationships with directors or executive officers, and no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.
- The press release included as Exhibit 99.1 was furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act, except as otherwise expressly provided.
Important Facts for Investors to Verify
- Confirm the July 1, 2024 effective date and Mr. Schwaneke’s resignation from the Board.
- Review the employment agreement and offer letter when filed with the Form 10-Q for the quarter ending June 30, 2024.
- Verify the vesting, performance conditions, share-price hurdle and change-in-control provisions for the RSUs, PSUs and options.
- Assess the aggregate potential compensation commitments, including the $3.5 million fiscal 2024 award, potential $3.5 million fiscal 2025 award and $300,000 sign-on bonus.
- Confirm the identity and transition arrangements for the prior CFO, which are not described in the provided filing text.